Sarepta Therapeutics is a U.S. commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying Duchenne muscular dystrophy (DMD) drug candidates.
Follow–Up Data Completed to Evaluate Safety and Effectiveness of Resten–MP in the Reduction of In–Stent Cardiovascular Restenosis BLOOMINGTON, Ind. (July 9, 2007) — Cook Medical announced completion of target patient enrollment and six–month follow–up data in phase II of the APPRAISAL clinical
Transitioning an Antisense Pioneer into a Leading RNA–based Drug Discovery and Development Company September 10, 2008. Harvard Club NYC 07.30 — 10.30 a.m. Dr. Leslie Hudson, President and CEO, AVI BioPharma RNA–based drug discovery and development Professor Francesco Muntoni, Professor of
Transitioning an Antisense Pioneer into a Leading RNA–based Drug Discovery and Development Company September 10, 2008 Dr. Leslie Hudson, President and CEO, AVI BioPharma RNA–based drug discovery and development Audio (MP3) , Slides (PDF) Professor Francesco Muntoni, Professor of Pediatric
Moderator: Denis Burger November 15, 2006 8:00 a.m. Pacific Time Operator: Ladies and gentlemen, welcome to the AVI BioPharma 2006 Third Quarter Financial Results conference call. At this time all participants are in a listen–only mode. Following management’s prepared remarks we will hold a Q&A
Action Duchenne provides $1.2m to support continuing development of drugs to treat Duchenne Muscular Dystrophy For Immediate Release CORVALLIS, OR., and. London, UK — July 28, 2009 — AVI BioPharma, Inc. (Nasdaq: AVII), a developer of RNA-based drugs, and Action Duchenne, a leading UK charity
For Immediate Release PORTLAND, OR — January 12, 2009 — AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA–based drugs, announced today new pre–clinical results published in Proceedings of the National Academy of Sciences (Saovaros Svasti et al (January 12, 2009) Proc. Natl Acad. Sci.
Also Published Is an Editorial, Beyond Antibiotics: New Horizons in Treating Burkholderia Species Infections, Commenting on the Studies BOTHELL, WA, May 07, 2010 (MARKETWIRE via COMTEX) --AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs, and its collaborators, including the
PORTLAND, Ore.--(BUSINESS WIRE)--March 13, 2006-- Cook to Fund All Clinical Development of Three Products for Cardiovascular Restenosis and Develop Products for Peripheral Vascular Diseases AVI BioPharma, Inc. (Nasdaq: AVII), today announced that it has entered into agreements with Cook Group Inc.
PORTLAND, Ore. & OMAHA, Neb.--(BUSINESS WIRE)--Jan. 9, 2007--AVI BioPharma, Inc. (Nasdaq:AVII), and Eleos Inc. announced today a cross-license agreement for the development of antisense drugs targeting p53, a well-studied human protein that controls cellular response to genetic damage.
PORTLAND, Ore. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Dec. 20, 2006--AVI BioPharma, Inc. (Nasdaq:AVII), and Ercole Biotech, Inc., announced today a cross-license and collaboration agreement to identify and develop drugs that direct the splicing of messenger RNA (mRNA) to treat a variety
This section of our website may contain dated or archived information which should not be considered current and may no longer be accurate. For current information, you are encouraged to review our most recent official corporate documents on file with the U.S. Securities and Exchange Commission.